Boundless Bio, Inc. (BOLD) Financial Statements (2026 and earlier)

Company Profile

Business Address 10955 ALEXANDRIA WAY
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
MRQ
12/31/2025
12/31/2024
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:107,600,000152,100,000
Cash and cash equivalent17,868,00026,587,000
Short-term investments89,713,000125,527,000
Other undisclosed cash, cash equivalents, and short-term investments19,000(14,000)
Other undisclosed current assets2,011,0002,290,000
Total current assets:109,611,000154,390,000
Noncurrent Assets
Operating lease, right-of-use asset43,659,00047,039,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization3,216,0004,321,000
Restricted cash and investments560,000560,000
Other undisclosed noncurrent assets13,00099,000
Total noncurrent assets:47,448,00052,019,000
TOTAL ASSETS:157,059,000206,409,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,727,0005,354,000
Accounts payable1,491,0001,274,000
Accrued liabilities3,160,0001,496,000
Other undisclosed accounts payable and accrued liabilities2,076,0002,584,000
Other undisclosed current liabilities5,810,0002,781,000
Total current liabilities:12,537,0008,135,000
Noncurrent Liabilities
Liabilities, other than long-term debt45,868,00047,632,000
Operating lease, liability45,868,00047,632,000
Total noncurrent liabilities:45,868,00047,632,000
Total liabilities:58,405,00055,767,000
Equity
Equity, attributable to parent98,654,000150,642,000
Common stock2,0002,000
Additional paid in capital358,257,000351,991,000
Accumulated other comprehensive income (loss)64,000121,000
Accumulated deficit(259,669,000)(201,472,000)
Total equity:98,654,000150,642,000
TOTAL LIABILITIES AND EQUITY:157,059,000206,409,000

Income Statement (P&L) (USD)

3/31/2026
TTM
12/31/2025
12/31/2024
Operating expenses(63,552,000)(73,267,000)
Operating loss:(63,552,000)(73,267,000)
Nonoperating income5,355,0007,904,000
Investment income, nonoperating5,357,0007,892,000
Net loss available to common stockholders, diluted:(58,197,000)(65,363,000)

Comprehensive Income (USD)

3/31/2026
TTM
12/31/2025
12/31/2024
Net loss:(58,197,000)(65,363,000)
Comprehensive loss:(58,197,000)(65,363,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(57,000)81,000
Comprehensive loss, net of tax, attributable to parent:(58,254,000)(65,282,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: